Insufficient weight loss (WL), weight re-gain and high attrition rates are common problems of any WL method. Intensive follow-up individualized to each patient is the suggested solution, but it is often unattainable due to financial restraints and lack of adequate human resources. Remote follow-up was conducted with a scale, provided by Allurion Technologies Inc., that was wirelessly connected with the patient’s smartphone and provided body composition analysis (RFWCS). Each patient was asked to send measurement by email or text weekly and received nutritional feedback. We compared %TBWL of: 1) Elipse intragastric balloon (Allurion Technologies, Inc.) at 16, 24 and 52 weeks with either biweekly office follow-up (BOF, N=12) or RFWCS (N=48); 2) 17 patients participating in non-surgical weight loss (NSWL) or bariatric surgery (BS) in a crossover design of equal time-intervals of BOF with or without RFWCS. The Elipse is a swallowable, fluid-filled balloon that is placed without endoscopy or anesthesia. It deflates and passes naturally at 16 weeks. Elipse patients on BOF or RFWCS had similar age (39.4±14.3 vs. 44.1±11.1), %females (63.6% vs. 72.3%) and BMI 36.1±3.2 vs. 36.9±6.2 kg/m2). %TBWL was similar at 16 (14.7%±7.5 vs. 13.8%±4.1) and 24 weeks (14%±9 vs. 13.3%±4.9), but RFWCS had better %TBWL at 52 weeks (5.9%±10.2 vs. 14.4%±7, p=.06). %TBWL of patients participating in NSWL or BS was better after RFWCS (0.93%±2.5 vs. 3.1%±2.7, p=.023) at an average of 7.2 weeks follow-up. RFWCS improves WL after various WL methods and it could be a used to achieve more intensive follow-up.